Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
716 (USA) · Dr. Ito
consented 2012-12-19
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate ATRIAL FLUTTER — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-19 (study day 32.0); relationship: POSSIBLE
moderate
assessed
Moderate BUNDLE BRANCH BLOCK RIGHT — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-19 (study day 32.0); relationship: POSSIBLE
moderate
assessed
Moderate VENTRICULAR SEPTAL DEFECT — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-01-19 (study day 32.0); relationship: POSSIBLE
Data queries
No data queries.